Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non–Small Cell Lung Cancer
Cancer Research and Treatment. 2023;55(3):851-864 
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines
Lung Cancer. 2012;78(3):193-200
A phase 1 trial of the MEK1/2 inhibitor AZD6244 in combination with thoracic radiotherapy in advanced non-small cell lung cancer (NSCLC)
Lung Cancer. 2010;67:S33-S34
Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines
Journal of Thoracic Oncology. 2009;4(2):161-166
P-967 Combination of MAPK inhibitor CI-1040 and conventional chemotherapeutic agents has synergistic effect in non-small cell lung cancer cell lines
Lung Cancer. 2005;49:S374
Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model
Molecular Therapy - Nucleic Acids. 2022;29:969-978
Effect of proton pump inhibitor on cell growth and sensitivity to cis-diamminedichloroplatinum (II) in non-small cell lung cancer cell lines
Lung Cancer. 1995;13(1):97
Synergistic Effect of Histone Deacetylase Inhibitor in Combination with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Egfr-Tki Resistant Non-Small Cell Lung Cancer Cell Lines
Annals of Oncology. 2015;26:i10
Antiproliferative effects of EGFR inhibitor Cetuximab and parp inhibitor combination on non-small cell lung cancer cell line A549 and cervical cancer cell line HeLa
Cellular and Molecular Biology. 2022;68(8):47-51
Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
Lung Cancer. 2012;76(1):26-31